CASE REPORT

‘The efficacy of extracorporeal liver support with molecular adsorbent recirculating system in severe drug-induced liver injury’

Jaishvi Eapen1, Rotimi Ayoola1,* and Ram M Subramanian2

1Department of Medicine, New York University, Langone Health, New York, NY, USA, and 2Department of Medicine, Division of Transplant Hepatology, Emory University, Atlanta, GA, USA

*Correspondence address: Department of Medicine, New York University, 150 55th St. Brooklyn, NY 11220, USA. Tel: +718-630-7000; Fax: +718-745-6092; E-mail: rotimi.ayoola@nyumc.org

Abstract

We report a case of a 26-year-old man with no significant medical history, who presented with fatigue, pruritus, jaundice, dark urine and clay colored stool for one month. He had been taking methyl-1-etiochoenol-epietiocholanolone, an androgenic anabolic steroid (AAS). He was initially found to have a total bilirubin (Tbili) of 6 mg/dL. He discontinued the AAS but the patients’ symptoms worsened and Tbili increased to 36 mg/dL. This prompted inpatient management of his drug-induced liver injury (DILI). Molecular adsorbent recirculating system (MARS) is an extracorporeal liver support system that replaces the detoxification function of the liver. The patient was initiated on a 4-day trial of MARS therapy. Over the course of his therapy, he clinically improved and his Tbili decreased to 20.7 mg/dL. At follow-up, his symptoms resolved and Tbili was 3.3 mg/dl. This case demonstrates the efficacy of MARS in treating severe cholestatic DILI refractory to standard medical therapy.

INTRODUCTION

Acute liver injury (ALI) is associated with high mortality. Drug-induced liver injury (DILI) is responsible for ~50% of cases of ALI in the USA [1, 2]. Extracorporeal liver assist devices can help achieve hemodynamic stability while patients with ALI await liver transplant, with the possibility of hepatic regeneration and recovery. Molecular Adsorbent Recirculating System (MARS) is an extracorporeal liver support system that replaces the detoxification function of the liver using an albumin-enriched dialysate to aid in the elimination of albumin-bound and water-soluble toxins [3].

CASE REPORT

A 26-year-old Caucasian male with no significant past medical history presented with fatigue, pruritus, jaundice, dark urine and clay colored stools for 1 month. He had been taking methyl-1-etiochoenol-epietiocholanolone, an androgenic anabolic steroid (AAS). He was initially found to have a total bilirubin (Tbili) of 6 mg/dL. He discontinued the AAS but the patients’ symptoms worsened and Tbili increased to 36 mg/dL. This prompted inpatient management of his drug-induced liver injury (DILI). Molecular adsorbent recirculating system (MARS) is an extracorporeal liver support system that replaces the detoxification function of the liver. The patient was initiated on a 4-day trial of MARS therapy. Over the course of his therapy, he clinically improved and his Tbili decreased to 20.7 mg/dL. At follow-up, his symptoms resolved and Tbili was 3.3 mg/dl. This case demonstrates the efficacy of MARS in treating severe cholestatic DILI refractory to standard medical therapy.
or hepatomegaly. Liver biochemistries revealed aspartate aminotransferase (AST) 67 U/l, alanine transaminase (ALT) 106 U/L, alkaline phosphatase 166 U/l, Tbilii 36 mg/dl, and international normalized ratio (INR) 0.95. Complete blood cell count (CBC) and Renal Function Panel (RFP) were normal. An extensive infectious, autoimmune, and metabolic work was negative. His abdominal ultrasound was normal.

At this stage, he was initiated on a 4-day trial of MARS therapy due to refractory hyperbilirubinemia after standard medical therapy (SMT). By day 3 of MARS therapy his pruritus, fatigue, hemoglobinuria and jaundice improved. Liver biochemistries at that time revealed AST 95 U/l, ALT 147 U/l, alkaline phosphatase 166 U/l, Tbilii 24.3 mg/dl and INR 1.01. CBC and RFP remained normal.

Over the course of his therapy, he remained hemodynamically stable, clinically improved and his Tbilii decreased to 20.7 mg/dl. A percutaneous liver biopsy was performed showing severe cholestasis with bile duct injury/inflammation and hepatocyte injury without steatosis (Fig. 1), consistent with DILI. Patient was discharge with outpatient follow-up.

At 2 months follow-up he ceased taking AAS and noted a resolution of his fatigue, jaundice, pruritus, and abnormal stool and urine color. Labs showed AST 56, ALT 104 and Tbilii 3.3 mg/dl.

Figure 1: Centrizonal parenchyma demonstrating severe cholestasis with formation of cholestatic rosettes, mild lymphocytic inflammation, reactive changes in hepatocytes, and an acidophil body (apoptotic hepatocyte). Hematoxylin and eosin stain, 400x overall magnification.

Abnormal Liver Function Tests

Obtain detailed history and physical, and medication list (including Herbal and Dietary supplements)

Calculate R value*

\[
R \text{ Value} = \frac{\text{Serum (ALT/ALT ULN)} + (\text{Alk P/Alk P ULN})}{2} < R \text{ Value} < 5 \\
R \text{ Value} > 5 \text{ (Hepatocellular)} \\
2 < R \text{ Value} < 5 \text{ (Mixed)} \\
R \text{ Value} < 2 \text{ (Cholestatic)}
\]

Initial Investigation: Acute viral hepatitis and autoimmune hepatitis serologies, imaging studies (e.g., abdominal ultrasound, computerized tomography)

Secondary Investigation: Case by case basis, ceruloplasmin, serologies for less common viruses, liver biopsy

Initial Investigation: Imaging (abdominal ultrasound, computerized tomography)

Secondary Investigation: Case by case basis, Cholangiography (either endoscopic or MR based), serologies for primary biliary cirrhosis, liver biopsy

Assessment of data, causality assessment and diagnosis:

1. Assessment of data:
   a. Completeness: Reasonable exclusion of all non-DILI etiologies
   b. Literature review by use of LiverTox and Pubmed
2. Clinical judgement for final DILI diagnosis
3. Expert Consultation if diagnosis remains uncertain

Figure 2: Flow chart for the diagnosis of DILI [4].
Table 1: Side effects of anabolic steroids by organ system

<table>
<thead>
<tr>
<th>Organ Systems</th>
<th>DISEASES</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIVER</td>
<td>Hepatitis, cholestatic hepatitis, Peliosis hepatis, hepatic adenoma, Hepatocellular carcinoma, Focal nodular hyperplasia</td>
</tr>
<tr>
<td>CARDIAC</td>
<td>Left ventricular hypertrophy, hypertension, myocardial infarction, arrhythmias</td>
</tr>
<tr>
<td>RENAL</td>
<td>Focal segmental glomerulosclerosis, cholemic nephrosis</td>
</tr>
<tr>
<td>NEUROPSYCHIATRIC</td>
<td>Depression, anxiety, addiction potential</td>
</tr>
</tbody>
</table>

DISCUSSION

DILI presents a challenging diagnosis for many physicians as its presentation can vary anywhere between acute fulminant hepatic failure to mild hepatitis. The American College of Gastroenterology created guidelines to help clinicians with the diagnosis of DILI (Fig. 2) [4]. DILI is a diagnosis of exclusion, in which proper history and correlating the use of the drug in question to the onset of the symptoms and lab abnormalities is key [5].

DILI can be due to numerous medications and/or drugs, both prescription and over the counter with >1000 estimated medications and supplements being implicated [6, 7]. DILI accounts for ~10% of all cases of acute hepatitis [8], and it is the most common cause of ALI in the USA [1, 9]. In this case, the patients’ previous history of similar symptoms after using AAS with use of another AAS, and hyperbilirubinemia pointed towards the diagnosis of DILI, with a percutaneous liver biopsy confirming the diagnosis.

AAS have grown tremendously in popularity especially amongst athletes and bodybuilders. Robles et al. reports a 3-fold increase in the number of AAS induced DILI cases over 1 decade, a total growth from 1 to 8% between 2000 and 2013 [10, 11]. Consequently, this upsurge of AAS use has not only led to increasing cases of DILI, but also to multi-organ side effects including cardiac dysfunction, neuropsychiatric disorders, and renal impairment (Table 1) [5, 10–14]. AAS DILI presents predominantly as cholestasis, but hepatocellular damage or both patterns can be seen [5]. It is postulated that the mechanism of cholestasis in AAS DILI is secondary to impaired excretion of bile rather than direct injury to the hepatocytes [11, 12].

Thus far, there has been no remedy for DILI other than SMT, which includes withdrawal of the offending agent and supportive care [12, 15]. Growing interest in MARS has led us to explore its use in DILI caused by AAS. In addition to water-soluble substances that are removed by renal replacement therapy, MARS has the added benefit of removing albumin-bound toxins from the patient’s serum (including bilirubin). This ability of MARS to remove albumin-bound toxins is facilitated by the use of an albumin dialysate and a dialysis membrane with the appropriate pore size. Due to this property of extracting albumin-bound toxins MARS addresses many of the consequences of DILI such as pruritus, cholestatic hepatitis, bile acid nephropathy and HE [15].

Though there is a paucity of clinical trials for the use of MARS in AAS DILI, there are prior case reports on this topic. Diaz et al. outlines a case series, which demonstrates successful therapy with MARS in four patients, all of whom consumed an AAS, and developed severe cholestatic jaundice refractory to SMT; MARS helped expedite their recovery [12]. Avegail et al. demonstrates the efficacy of MARS in patients with severe bile acid nephropathy and other forms of renal dysfunction more commonly seen with AAS DILI [9, 10]. Other case reports and series have reported an improvement in both symptoms (including jaundice, pruritus and confusion) and biochemical parameters after 3–4 sessions of MARS therapy.

In regards to acute liver failure (ALF) the use of MARS has not been fully established. MARS is a useful tool that has been shown to stabilize clinical conditions in ALF patients awaiting transplant, and facilitate hepatic regeneration. Several clinical trials have concluded MARS as a reasonable tool in ALF patients’ by reducing bilirubin levels, improving hemodynamic status, renal dysfunction and hepatic encephalopathy [16–18]. A multicenter, randomized, controlled trial involving patients with acute liver failure showed no survival benefit [18]. Although survival benefit has not been proven, it has the potential to benefit specific patient subgroups.

CONCLUSION

MARS has been reported to stabilize clinical parameters in patients with DILI and DILI associated ALI patients, with a goal to bridge the patient to spontaneous recovery or liver transplant. In the setting of cholestatic liver injury, MARS may be of particular benefit given its ability to extract bilirubin, which is an albumin-bound toxin. This case demonstrates the efficacy of MARS in treating severe cholestatic DILI due to AAS that was refractory to standard medical therapy.

CONFLICT OF INTEREST STATEMENT

Informed consent was obtained for publication of this case report. This case report in part has been previously presented as an abstract poster at American College of Gastroenterology 2015 Annual Scientific Meeting. It has thus been expanded and enriched from the abstract version.

AUTHORS’ ROLES

J.E. and R.A. drafted, reviewed and edited the manuscript. R.S. reviewed and edited the manuscript. R.A. is the article guarantor.

REFERENCES


